AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11725730 — intervention group
Group type: EXPERIMENTAL
Intervention: OC containing 0.020 mg of ethinyl estradiol (EE) and 0.15 mg of desogestrel (Group B)
Number of subjects: 64
Study 11725730 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 64
Study 9164358 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 42 micrograms twice daily
Number of subjects: 484
Study 9164358 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (extended-release)
Number of subjects: 484
Study 8341090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program for 3 months
Number of subjects: 44
Study 8341090 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 8341090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Number of subjects: 44
Study 2959198 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin regimen
Number of subjects: 47
Study 2959198 — intervention group
Group type: COMPARATOR
Intervention: Amikacin plus ceftazidime
Number of subjects: 47
Study 2959198 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin-ceftazidime-teicoplanin treatment
Number of subjects: 47
Study 29221844 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 45
Study 29221844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 27342755 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality training curriculum for laparoscopic sigmoid colectomy (8 attempts of 3 modules or full procedure)
Number of subjects: 33
Study 27342755 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality training curriculum for laparoscopic sigmoid colectomy
Number of subjects: 33
Study 27342755 — intervention group
Group type: COMPARATOR
Intervention: Benchmark criteria for experienced surgeons
Number of subjects: 33
Study 24797423 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 SQ‐HDM
Number of subjects: 604
Study 24797423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study 22086747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761® (240 mg once daily)
Number of subjects: 404
Study 22086747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 20803423 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie meal replacement with mixed rice
Number of subjects: 40
Study 20803423 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie meal replacement with white rice
Number of subjects: 40
Study 17961292 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling for 30 min at 65 % of maximum heart rate
Number of subjects: 12
Study 17961292 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 12
Study 15897360 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mean arterial pressure (MAP) < or =92
Number of subjects: 0
Study 15897360 — intervention group
Group type: COMPARATOR
Intervention: Usual MAP 102 to 107 mm Hg (Control)
Number of subjects: 0
Study 15897360 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (one of the antihypertensives)
Number of subjects: 0
Study 15897360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril and Metoprolol (other antihypertensives)
Number of subjects: 0
Study 12324674 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 400 micro g twice daily
Number of subjects: 259
Study 10397653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted inferior alveolar nerve block
Number of subjects: 40
Study 10397653 — intervention group
Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve block
Number of subjects: 40
Study 7595423 — intervention group
Group type: EXPERIMENTAL
Intervention: Snowman‐shaped outline with nine body parts read by an experimenter
Number of subjects: 28
Study 7595423 — intervention group
Group type: COMPARATOR
Intervention: Pointing to body parts on themselves
Number of subjects: 28
Study 7595423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadpole‐person drawers
Number of subjects: 28
Study 2258518 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection Control Liaison Nurse (ICLN) education and tutorials for ward nurses
Number of subjects: 27
Study 2258518 — intervention group
Group type: COMPARATOR
Intervention: Control group with no ICLN involvement, only receiving in-service lectures from the Infection Control Nurse (ICN)
Number of subjects: 27
Study 6103579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 154
Study 6103579 — intervention group
Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 154
Study 6103579 — intervention group
Group type: COMPARATOR
Intervention: Cromoglycate
Number of subjects: 154
Study 29063424 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 40
Study 29063424 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 40
Study 27389248 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific, evidence-based reminders generated by a multi-specialty decision support system
Number of subjects: 0
Study 27389248 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific, evidence-based reminders for venous thromboembolism (VTE) prevention
Number of subjects: 0
Study 25503163 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus lafutidine
Number of subjects: 0
Study 25503163 — intervention group
Group type: COMPARATOR
Intervention: S‐1
Number of subjects: 0
Study 22583583 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rebonding with round bur for adhesive removal
Number of subjects: 68
Study 22583583 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed rebonding with tungsten carbide bur for adhesive removal
Number of subjects: 68
Study 22583583 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed rebonding with green rubber wheel for adhesive removal
Number of subjects: 68
Study 22583583 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed rebonding after one month in a simulated oral environment
Number of subjects: 68
Study 20869557 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 percent foam‐based ciprofloxacin (FoamOtic Cipro)
Number of subjects: 63
Study 20869557 — intervention group
Group type: COMPARATOR
Intervention: 0.3 percent solution‐based ciprofloxacin (Ciloxan)
Number of subjects: 63
Study 18251035 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based learning module (WM)
Number of subjects: 3
Study 18251035 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group PRM instruction (SG)
Number of subjects: 3
Study 18251035 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard classroom instruction (CI)
Number of subjects: 3
Study 15851401 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (daily antioxidant powder containing riboflavin, vitamin E, selenium, and N-acetylcysteine for 20 weeks)
Number of subjects: 2332
Study 15851401 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 20 weeks)
Number of subjects: 2332
Study 15851401 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 2332
Study 15851401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2332
Study 12844385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil capsules containing 400 mg DHA/g (200 mg/d) (n=50)
Number of subjects: 100
Study 12844385 — intervention group
Group type: COMPARATOR
Intervention: Placebo containing 810 mg oleic acid/g (400 mg/d) (n=50)
Number of subjects: 100
Study 11077510 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced intake of saturated fat
Number of subjects: 0
Study 11077510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of fish, fish oils, and alpha-linolenic acid
Number of subjects: 0
Study 11077510 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid, vitamin B6, and B12
Number of subjects: 0
Study 11077510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of nuts
Number of subjects: 0
Study 11077510 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols and psyllium
Number of subjects: 0
Study 8783998 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct infusion of shed mediastinal blood (Group I)
Number of subjects: 40
Study 8783998 — intervention group
Group type: COMPARATOR
Intervention: Not infusing shed mediastinal blood (Group II)
Number of subjects: 40
Study 1536437 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 45
Study 1536437 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 45
Study 1536437 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 45
Study 6539812 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (2 mg/kg intravenous every two hours for five doses)
Number of subjects: 28
Study 6539812 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (3 mg intravenous every two hours for five doses)
Number of subjects: 28
Study 30615646 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron with folic acid supplementation (IFAS)
Number of subjects: 262
Study 30615646 — intervention group
Group type: EXPERIMENTAL
Intervention: IFAS counseling
Number of subjects: 262
Study 30615646 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about IFAS
Number of subjects: 262
Study 30615646 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravidity
Number of subjects: 262
Study 30615646 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age at first ANC visit
Number of subjects: 262
Study 30615646 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice about IFAS
Number of subjects: 262
Study 30615646 — intervention group
Group type: EXPERIMENTAL
Intervention: Current anemia
Number of subjects: 262
Study 29199384 — intervention group
Group type: EXPERIMENTAL
Intervention: LED therapy (658 nm) with 40 mW, 7 J/cm2 on every other day
Number of subjects: 5
Study 29199384 — intervention group
Group type: COMPARATOR
Intervention: Placebo (contralateral limb)
Number of subjects: 5
Study 26760085 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost mesh
Number of subjects: 302
Study 26760085 — intervention group
Group type: COMPARATOR
Intervention: Commercial mesh
Number of subjects: 302
Study 26050706 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral N-acetylcysteine (NAC) twice daily during AmB treatment
Number of subjects: 54
Study 26050706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 22275504 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous CIK cell immunotherapy
Number of subjects: 148
Study 22275504 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-2 treatment combination with IFN-α-2a
Number of subjects: 148
Study 20637967 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-mg/24-hour patch
Number of subjects: 50
Study 20637967 — intervention group
Group type: COMPARATOR
Intervention: 25-mg/16-hour patch
Number of subjects: 50
Study 20637967 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-mg/24-hour patch (16-hour application time)
Number of subjects: 50
Study 18341602 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD + 24% EDTA conditioning + EMD application
Number of subjects: 15
Study 18341602 — intervention group
Group type: COMPARATOR
Intervention: OFD + 24% EDTA conditioning
Number of subjects: 15
Study 16466061 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc sulphate (50 mg of elemental zinc)
Number of subjects: 66
Study 16466061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 14675012 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD programmed to a lower limit of VT detection at 128 beats/min (group I, n = 44)
Number of subjects: 90
Study 14675012 — intervention group
Group type: COMPARATOR
Intervention: ICD programmed to a lower limit of VT detection at 153 beats/min (group II, n = 46)
Number of subjects: 90
Study 14675012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 14675012 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for tachycardias <153 beats/min
Number of subjects: 90
Study 10616135 — intervention group
Group type: EXPERIMENTAL
Intervention: Embase standard searches (index terms only)
Number of subjects: 0
Study 10616135 — intervention group
Group type: EXPERIMENTAL
Intervention: Medline standard searches (index terms only)
Number of subjects: 0
Study 10616135 — intervention group
Group type: EXPERIMENTAL
Intervention: PsycINFO standard searches (index terms only)
Number of subjects: 0
Study 10616135 — intervention group
Group type: EXPERIMENTAL
Intervention: Embase expert searches (index and free text terms)
Number of subjects: 0
Study 10616135 — intervention group
Group type: EXPERIMENTAL
Intervention: Medline expert searches (index and free text terms)
Number of subjects: 0
Study 10616135 — intervention group
Group type: EXPERIMENTAL
Intervention: PsycINFO expert searches (index and free text terms)
Number of subjects: 0
Study 10616135 — intervention group
Group type: COMPARATOR
Intervention: Medline
Number of subjects: 0
Study 8693439 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise challenge with dry air (8 minutes of cycle exercise at 60% maximum voluntary ventilation)
Number of subjects: 109
Study 1988516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (Amp)
Number of subjects: 85
Study 1988516 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP/SMZ)
Number of subjects: 85
Study 6325720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg
Number of subjects: 10
Study 6325720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29533260 — intervention group
Group type: EXPERIMENTAL
Intervention: Aron Alpha A adhesive applied at 2 sites along the catheter with film dressing
Number of subjects: 55
Study 29533260 — intervention group
Group type: COMPARATOR
Intervention: Film dressing alone (Control)
Number of subjects: 55
Study 29675792 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 955
Study 29675792 — intervention group
Group type: COMPARATOR
Intervention: No maintenance
Number of subjects: 955
Study 27097785 — intervention group
Group type: EXPERIMENTAL
Intervention: High load lifting exercise
Number of subjects: 70
Study 27097785 — intervention group
Group type: COMPARATOR
Intervention: Low load motor control exercises
Number of subjects: 70
Study 22952213 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban 15 mg bid
Number of subjects: 2
Study 22952213 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban 30 mg bid
Number of subjects: 2
Study 22952213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 19827464 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% maltodextrin solution (CHO)
Number of subjects: 14
Study 19827464 — intervention group
Group type: COMPARATOR
Intervention: Water (PLA)
Number of subjects: 14
Study 15637686 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) screening
Number of subjects: 0
Study 15637686 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12611212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ministernotomy approach (group Gm)
Number of subjects: 98
Study 12611212 — intervention group
Group type: COMPARATOR
Intervention: Standard total sternotomy approach (group Gs)
Number of subjects: 98
Study 9413354 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine (0.5 to 3 g/m2 daily for 6 to 12 months in phase 1; 0.5 g/m2 for 12 months in phase 2)
Number of subjects: 66
Study 9413354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 8189347 — intervention group
Group type: EXPERIMENTAL
Intervention: High status in-group
Number of subjects: 0
Study 8189347 — intervention group
Group type: COMPARATOR
Intervention: Low status in-group
Number of subjects: 0
Study 8189347 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative in-group size
Number of subjects: 0
Study 3555956 — intervention group
Group type: EXPERIMENTAL
Intervention: Velosulin/Insulatard
Number of subjects: 12
Study 3555956 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-synthetic human insulin
Number of subjects: 12
Study 3555956 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment periods in chronological order
Number of subjects: 12
Study 3555956 — intervention group
Group type: COMPARATOR
Intervention: All regimens
Number of subjects: 12
Study 30666366 — intervention group
Group type: EXPERIMENTAL
Intervention: SOMS-guided mobility treatment with a facilitator
Number of subjects: 200
Study 30666366 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study 30541536 — intervention group
Group type: EXPERIMENTAL
Intervention: e-IMR + IMR
Number of subjects: 60
Study 30541536 — intervention group
Group type: COMPARATOR
Intervention: IMR only
Number of subjects: 60
Study 26863870 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 36
Study 26863870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 36
Study 24606242 — intervention group
Group type: EXPERIMENTAL
Intervention: NoRx (open-label 'no treatment')
Number of subjects: 21
Study 24606242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (patient-blinded)
Number of subjects: 21
Study 23272490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized house dust mite extract
Number of subjects: 157
Study 20873892 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-specific biannual personalized normative feedback (PNF)
Number of subjects: 818
Study 20873892 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 818
Study 18187431 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan (Propol) 2 x 1.3 gr daily for two months
Number of subjects: 48
Study 18187431 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder daily for two months
Number of subjects: 48
Study 15210522 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryonic tissue implants
Number of subjects: 40
Study 15210522 — intervention group
Group type: COMPARATOR
Intervention: Sham operation (placebo)
Number of subjects: 40
Study 11454015 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (GF), 600 mg b.i.d. for 12 weeks
Number of subjects: 10
Study 11454015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9683392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereals fortified with 200 microg of folic acid per portion
Number of subjects: 119
Study 9683392 — intervention group
Group type: COMPARATOR
Intervention: Unfortified cereals
Number of subjects: 119
Study 7823273 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration with metronidazole gel (25%, 250 mg/g)
Number of subjects: 12
Study 7823273 — intervention group
Group type: COMPARATOR
Intervention: Guided tissue regeneration without metronidazole gel (control)
Number of subjects: 12
Study 2898321 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg metaclazepam per day for 13 days
Number of subjects: 50
Study 2898321 — intervention group
Group type: COMPARATOR
Intervention: 4 mg bromazepam per day for 13 days
Number of subjects: 50
Study 30133674 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive laparoscopic esophagectomy (EMIL)
Number of subjects: 30
Study 30133674 — intervention group
Group type: COMPARATOR
Intervention: Open trans-hiatal esophagectomy (ETHA)
Number of subjects: 30
Study 28348155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 781
Study 28348155 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 781
Study 26084366 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal iron plus folic acid supplementation
Number of subjects: 1744
Study 26084366 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimicronutrient supplementation
Number of subjects: 1744
Study 26084366 — intervention group
Group type: COMPARATOR
Intervention: Prenatal folic acid supplementation
Number of subjects: 1744
Study 24140602 — intervention group
Group type: EXPERIMENTAL
Intervention: SHD-RU486 group
Number of subjects: 90
Study 24140602 — intervention group
Group type: COMPARATOR
Intervention: RU486 group
Number of subjects: 90
Study 21316208 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (220 mg/day)
Number of subjects: 114
Study 21316208 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA+AA (220 mg/day)
Number of subjects: 114
Study 21316208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 18494204 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 100
Study 18494204 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy in open cholecystectomy
Number of subjects: 100
Study 18494204 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 100
Study 17159063 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-defibrillator therapy
Number of subjects: 1520
Study 17159063 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 1520
Study 17159063 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT therapy
Number of subjects: 1520
Study 17159063 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction >20%
Number of subjects: 1520
Study 17159063 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration >160 ms
Number of subjects: 1520
Study 17159063 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1520
Study 17159063 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced NYHA class IV heart failure
Number of subjects: 1520
Study 17159063 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal dysfunction
Number of subjects: 1520
Study 17159063 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender in CRT-defibrillator patients
Number of subjects: 1520
Study 17159063 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of neurohormonal antagonists
Number of subjects: 1520
Study 17159063 — intervention group
Group type: EXPERIMENTAL
Intervention: Class IV heart failure status
Number of subjects: 1520
Study 17159063 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate ICD therapy
Number of subjects: 1520